BioStock Studio: Gabather gives clinical trial update

Gabather’s top candidate GT-002 for treating psychiatric or mood disorders like depression, anxiety, and schizophrenia is currently in the early stages of clinical development.

The company is planning a key target engagement study in healthy volunteers aimed at showing how GT-002 modulates brain activity at both the functional and regional levels of the brain. The company’s CEO Michael-Robin.